The short answer
Cultured cells secrete IGF binding proteins into their medium, which sequester added IGF-1 to an extent that varies between cell types and conditions. An analogue resistant to those binding proteins delivers more consistent availability, which is the application LR3 was developed for.
Key facts
- Established use
- Cell culture supplement
- Problem addressed
- Secreted IGFBPs in medium
- Benefit
- Consistent availability across conditions
- Why it matters
- Reproducibility between experiments
- Context
- In vitro laboratory work
- Primary literature under 'LR3'
- Almost none
The problem in a culture dish
Add native IGF-1 to a culture and an unpredictable fraction is immediately bound by binding proteins the cells themselves have secreted. How much depends on cell type, density, medium composition and how long the culture has been running. The nominal concentration and the effective concentration diverge, and they diverge differently each time.
Why that undermines an experiment
Comparing conditions requires that the variable under study is the one that differs. If the effective IGF-1 concentration varies with cell density, then a density experiment and a concentration experiment are confounded with each other. Removing that coupling is worth real effort.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
What the analogue provides
Reduced binding protein affinity means less of what is added disappears into complexes, so the nominal and effective concentrations track more closely. That is a reproducibility gain rather than a potency gain, and it is a real methodological improvement for in vitro work.
Why this context matters for reading everything else
LR3 was engineered for a dish, where bypassing binding protein regulation is desirable because that regulation is an experimental nuisance. In an organism the same system is a control mechanism on a growth factor acting on nearly every tissue. A design that is sensible in vitro is not automatically sensible anywhere else, and the reasoning does not transfer.
The literature gap
Searches for IGF-1 LR3 and Long R3 IGF-1 return no primary research literature under those names. The compound is real and its design rationale is sound, but it exists as a reagent rather than as a research subject. Anyone expecting to find trials of it will not.
Frequently asked questions
Why do cultured cells interfere with added IGF-1?
They secrete their own IGF binding proteins into the medium, which sequester a variable fraction of what is added.
Is LR3 more potent than native IGF-1?
The benefit is consistency of availability, not intrinsic potency. Less of what is added disappears into complexes.
Is there research literature on LR3 specifically?
Almost none under that name. It exists as a laboratory reagent rather than as a research subject.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- IGF-1 LR3 Storage: A Folded Protein, Not a PeptideA folded protein can lose activity while remaining chemically intact. Why denaturation and adsorption matter more here than chemical degradation.
- How to Verify a Protein With No PubChem RecordIGF-1 is not in PubChem - proteins are indexed in UniProt instead. What that means for checking a certificate, and what a certificate should carry.
- IGF-1 LR3 and Anti-Doping StatusIGF-1 and its analogues sit in WADA class S2, prohibited in and out of competition. What that classification covers and why it is unconditional.
- IGF-1 LR3 Regulatory StatusNo marketing authorisation anywhere, though an approved native rhIGF-1 exists. Why that distinction is the important one in this category.
- A Natural Experiment in Absent IGF-1People with growth hormone receptor deficiency produce almost no IGF-1. Laron and Werner report that they do not develop cancer.